[SCHEDULE 13G/A] CORCEPT THERAPEUTICS INC Amended Passive Investment Disclosure

Q: What does the Schedule 13G/A amendment say about The Vanguard Group's holdings in CORT?

The amendment states The Vanguard Group reports 0 shares beneficially owned in Corcept Therapeutics common stock. It specifies 0% of the class and zero voting and dispositive powers as disclosed in the filing.

Q: Why did Vanguard change how it reports ownership for Corcept Therapeutics (CORT)?

Vanguard describes an internal realignment on January 12, 2026 that disaggregated certain subsidiaries' reporting. In reliance on SEC Release No. 34-39538 , those entities will report beneficial ownership separately from The Vanguard Group, Inc.

Q: Who signed the Schedule 13G/A amendment for Vanguard regarding CORT?

The filing is signed by Ashley Grim , Head of Global Fund Administration, with a signature date of 03/26/2026. The signature block appears at the end of the amendment.

[SCHEDULE 13G/A] CORCEPT THERAPEUTICS INC Amended Passive Investment Disclosure

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting 0 shares of Corcept Therapeutics Inc. common stock. The amendment states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538.

The filing lists amount beneficially owned: 0 and percent of class: 0%, and is signed by Ashley Grim on 03/26/2026. The Vanguard Group indicates no single other person holds more than 5% of the reported securities.

03/26/2026 - 05:43 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

Corcept Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

The Vanguard Group

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

Sec Use Only

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

0 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/26/2026

Source: View Original Filing on SEC EDGAR

FAQ

What does the Schedule 13G/A amendment say about The Vanguard Group's holdings in CORT?

The amendment states The Vanguard Group reports 0 shares beneficially owned in Corcept Therapeutics common stock. It specifies 0% of the class and zero voting and dispositive powers as disclosed in the filing.

Why did Vanguard change how it reports ownership for Corcept Therapeutics (CORT)?

Vanguard describes an internal realignment on January 12, 2026 that disaggregated certain subsidiaries' reporting. In reliance on SEC Release No. 34-39538, those entities will report beneficial ownership separately from The Vanguard Group, Inc.

Who signed the Schedule 13G/A amendment for Vanguard regarding CORT?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026. The signature block appears at the end of the amendment.

Does the filing identify any person holding more than 5% of CORT shares on Vanguard's behalf?

The amendment states that no other person's interest reported herein is more than 5%. It also notes that listed investment company shareholders or beneficiaries need not be named under the Investment Company Act.

What voting and dispositive powers does Vanguard claim for CORT shares in the amendment?

The Schedule 13G/A reports 0 shares for each category: sole voting power, shared voting power, sole dispositive power, and shared dispositive power. Each of these fields is listed as 0 in the filing.

When did Vanguard's internal realignment referenced in the CORT filing occur?

The amendment specifies the internal realignment occurred on January 12, 2026. The filing cites SEC Release No. 34-39538 as the basis for subsequent disaggregated reporting by subsidiaries.

[SCHEDULE 13G/A] CORCEPT THERAPEUTICS INC Amended Passive Investment Disclosure

Rhea-AI Filing Summary

Positive

Negative

FAQ

What does the Schedule 13G/A amendment say about The Vanguard Group's holdings in CORT?

Why did Vanguard change how it reports ownership for Corcept Therapeutics (CORT)?

Who signed the Schedule 13G/A amendment for Vanguard regarding CORT?

Does the filing identify any person holding more than 5% of CORT shares on Vanguard's behalf?

What voting and dispositive powers does Vanguard claim for CORT shares in the amendment?

When did Vanguard's internal realignment referenced in the CORT filing occur?

NASDAQ:CORT

CORT Rankings

CORT Latest News

CORT Latest SEC Filings

CORT Stock Data

Trending News

[SCHEDULE 13G/A] CORCEPT THERAPEUTICS INC Amended Passive Investment Disclosure

Rhea-AI Filing Summary

Positive

Negative

FAQ

What does the Schedule 13G/A amendment say about The Vanguard Group's holdings in CORT?

Why did Vanguard change how it reports ownership for Corcept Therapeutics (CORT)?

Who signed the Schedule 13G/A amendment for Vanguard regarding CORT?

Does the filing identify any person holding more than 5% of CORT shares on Vanguard's behalf?

What voting and dispositive powers does Vanguard claim for CORT shares in the amendment?

When did Vanguard's internal realignment referenced in the CORT filing occur?

NASDAQ:CORT

CORT Rankings

CORT Latest News

CORT Latest SEC Filings

CORT Stock Data